Empty Waymo cars are converging on one Atlanta cul-de-sac. No one can explain why
A normally quiet Atlanta neighborhood has suddenly found itself flooded with traffic early in the mo…
fastcompany.com
URGN(URGN)
URGN
Next earnings: Aug 6, 2026 · Before open
Signal
Bearish Setup1!1↓
PRICE
Prev Close
29.68
Open
29.26
Day Range28.26 – 29.59
28.26
29.59
52W Range3.42 – 32.37
3.42
32.37
88% of range
VOLUME & SIZE
Avg Volume
891.2K
FUNDAMENTALS
P/E Ratio
-10.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.05
Market-like
Performance
1D↓
-3.03%5D
+6.79%1M
+33.80%3M
+43.18%6M
+21.13%YTD
+22.89%1Y↑
+192.18%Best: 1Y (+192.18%)Worst: 1D (-3.03%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +53% YoY · 90% gross marginValuation
FAIR
P/E not availableHealth
WEAK
CR 4.7 · FCF negativeLean Bullish
Key MetricsTTM
Market Cap$1.40B
Revenue TTM$140.49M
Net Income TTM-$133.22M
Free Cash Flow-$166.03M
Gross Margin89.9%
Net Margin-94.8%
Operating Margin-77.0%
Return on Equity121.5%
Return on Assets-52.5%
Debt / Equity-1.59
Current Ratio4.69
EPS TTM$-2.65
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
4 strong2 concern
67/100Liquidity
4.69Strong
Leverage
-1.59Strong
Coverage
-2.8xConcern
ROE
121.5%Strong
ROIC
-50.9%Concern
Cash
$111MStrong
ANALYST COVERAGE15 analysts
BUY
▲ +47.7%upside to target
L $40.00
Med $42.50consensus
H $45.00Stock Health
Composite Score
4 of 5 signals bullish
9/10
Technicals
●
~RSI RangeRSI 73 — Overbought, caution
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 4.69 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 17, 2026
In 93 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ UptrendGolden Cross · 50D leads 200D by 4.7%
+31.1% vs SMA 50 · +37.2% vs SMA 200
Momentum
RSI72.7Overbought — pullback risk
MACD+2.43Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$32.37+12.5%
Current
$28.78
EMA 50
$23.90-17.0%
EMA 200
$20.07-30.3%
52W Low
$3.42-88.1%
52-Week RangeNear 52-week high
$3.4288th %ile$32.37
Squeeze SetupVolume-based
Moderate Squeeze SetupAccumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
20-Day Money Flow
Acc days:8
Dist days:3
Edge:+5 acc
Volume Context
Avg Vol (50D)846K
Recent Vol (5D)
985K+16%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 7 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $111.9M $109.0M–$116.8M | — | -$3.20 | — | ±6% | High6 |
FY2026(current) | $263.3M $239.6M–$301.6M | ▲ +135.3% | -$0.89 | — | ±50% | High7 |
FY2027 | $436.8M $385.1M–$488.5M | ▲ +65.9% | $1.44 | — | ±50% | High7 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryURGN
Last 8Q
-1.9%avg beat
Beat 3 of 8 quartersMissed 5↑ Estimates rising-11%
Q3'24
+35%
Q4'24
-16%
Q1'25
-11%
Q2'25
-28%
Q3'25
+4%
Q4'25
-4%
Q1'26
+16%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightAnalyst Activity
All ratings →No recent activity
H.C. WainwrightNeutral → Buy
Jun 16
UPGRADE
H.C. WainwrightBuy → Neutral
May 22
DOWNGRADE
Keefe, Bruyette & W…Outperform
Jun 14
UPGRADE
Insider Activity
SEC Filings →0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $300K sold · 30d window
Schoenberg MarkChief Medical …
$300K
May 8
SELL
Smith Jason DrewGeneral Counsel
$63K
Feb 3
SELL
Smith Jason DrewGeneral Counsel
$52K
Feb 3
SELL
Smith Jason DrewGeneral Counsel
$32K
Feb 3
SELL
Schoenberg MarkChief Medical …
$36K
Feb 3
SELL
Schoenberg MarkChief Medical …
$36K
Feb 3
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
2.8M▲2
Jefferies Financial Group Inc.
2.2M—3
SG Americas Securities, LLC
1.7M▲4
SILVERARC CAPITAL MANAGEMENT, LLC
1.5M▼5
MENORA MIVTACHIM HOLDINGS LTD.
1.2M—6
Migdal Insurance & Financial Holdings Ltd.
771K—7
Soleus Capital Management, L.P.
727K▲8
SUPERSTRING CAPITAL MANAGEMENT LP
387K▼News & Activity
URGN News
20 articles · 4h ago
LegalZoom: Premium Subscription Packages Are Driving Growth
seekingalpha.com
Here's How Much Traders See Home Depot Stock Moving After Earnings
investopedia.com
Finning International Q1 Earnings Call Highlights
marketbeat.com
goeasy Q1 Earnings Call Highlights
marketbeat.com
Hydro One Q1 Earnings Call Highlights
marketbeat.com
ExlService Holdings, Inc. (EXLS) Analyst/Investor Day Transcript
seekingalpha.com
PEDEVCO Corp. (PED) Q1 2026 Earnings Call Transcript
seekingalpha.com
TSI: Not Well-Positioned For The Current Environment, And NAV Is Declining
seekingalpha.com
OpenAI seals deal in Malta to give all Maltese access to ChatGPT Plus
reuters.com
AVK: Offers A Double-Digit Yield At A Discounted Valuation
seekingalpha.com
The resale OG is back: How eBay won over fashion shoppers again
businessinsider.com
Got $5,000? Cameco Could Be the Nuclear Fuel Champion That Turns Today's Energy Crisis Into Long‑Term Wealth.
fool.com
Why DBA's Five Year Lead Over WEAT Vanished in Just Five Days
247wallst.com
DATA Communications Management Q1 Earnings Call Highlights
marketbeat.com
Dream Unlimited Q1 Earnings Call Highlights
marketbeat.com
VerticalScope Q1 Earnings Call Highlights
marketbeat.com
Freehold Royalties Q1 Earnings Call Highlights
marketbeat.com
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
marketbeat.com
Celsius: Competition Concerns Create A Compelling Buying Opportunity
seekingalpha.com
About
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Elizabeth Barrett
Country
Israel
Website
Timothy SimonSenior Vice President of Business Development & Portfolio Strategy
Alison HardgroveSenior Vice President of Human Resources
Elizabeth A. BarrettPresident, Chief Executive Officer & Director
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
URGN◀ | $28.78 | -3.03% | $1.4B | — | +2145.0% | -13980.9% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.98% | — | 50.3 | +342156.2% | -5499.2% | 1500 |